In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have
shown excellent clinical results. However, even the latest-generation drug-eluting stent has …

Abstract Background: The Absorb everolimus-eluting poly-L-lactic acid–based
bioresorbable vascular scaffold (BVS) provides early drug delivery and mechanical support …

Background: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3
years after coronary artery implantation. The safety and effectiveness of BVS through this …

The Japanese Circulation Society (JCS) published the “Guidelines for elective percutaneous
coronary intervention [PCI] in patients with stable coronary disease” in 2000. In 2006 …

Background: Procedural technique may affect clinical outcomes after bioresorbable vascular
scaffold (BVS) implantation. Prior studies suggesting such a relationship have not adjusted …

Introduction: The first-generation bioresorbable scaffolds (BRSs) had a large strut profile to
compensate for the insufficient radial strength of bioresorbable polymer materials, resulting …

Cardiovascular disease is a major concern for patients with end-stage renal disease
(ESRD), especially those on hemodialysis. ESRD patients with coronary artery disease often …

Fluoroscopy severely underestimates the presence of endoluminal calcium, and the calcium
detected on fluoroscopy is sometimes localized at the interface between the adventitia and …

Current poly‐l‐lactide acid (PLLA) scaffolds have issues of inadequate mechanical strength
leading to thrombosis formation. Designing a novel bioabsorbable PLLA stent with a novel …

Recent reports of randomised trials (ABSORB II, ABSORB Japan and ABSORB China) have
raised questions on the “non” non-inferiority of the acute and long-term performance of the …